PMID- 18506587
OWN - NLM
STAT- MEDLINE
DCOM- 20080916
LR  - 20211020
IS  - 0262-0898 (Print)
IS  - 1573-7276 (Electronic)
IS  - 0262-0898 (Linking)
VI  - 25
IP  - 5
DP  - 2008
TI  - Intraosseous injection of RM1 murine prostate cancer cells promotes rapid 
      osteolysis and periosteal bone deposition.
PG  - 581-90
LID - 10.1007/s10585-008-9175-1 [doi]
AB  - The molecular mechanisms associated with prostate cancer (PCa) progression within 
      bone remain a topic of intense investigation. With the availability of transgenic 
      mouse strains, a model of PCa for use in immune competent/transgenic mice would 
      be highly beneficial. This study was designed to explore the utility of RM1 mouse 
      PCa cells in investigations of tumor:bone interactions. The efficacies of several 
      implantation techniques were examined for reliably producing intra-bone RM1 tumor 
      growth and bone lesion formation in immune competent mice. Longitudinal 
      monitoring of bone remodeling and lesion phenotypes was conducted by 
      microcomputed tomography (muCT) and histological analyses. Our results indicate 
      that direct intrabone injections of RM1 cells are necessary for tumor growth 
      within bone and direct implantation promotes the rapid development of osteolytic 
      bone lesions with periosteal bone deposition post-cortical breach. In vitro, RM1 
      cells promote the proliferation of osteoblast (MC3T3-E1) and osteoclast 
      (Raw264.7) progenitors in a dose dependent manner. Conditioned culture media from 
      RM1 cells appears to promote earlier expression of genes/proteins associated with 
      osteoblastic differentiation. While clearly stimulating osteoclast function in 
      vivo, RM1 cells had little effect on differentiation and tartate resistant acid 
      phosphatase (TRAP) expression by Raw264.7 cells. These data, coupled with in vivo 
      muCT images, indicate the ability of RM1 cells to induce mixed, yet 
      predominentally osteolytic, responses in bone and illustrate the potential of RM1 
      cells as a model of investigating prostate tumor:stroma interactions in immune 
      competent/transgenic mice on a C57BL/6 background.
FAU - McCabe, N Patrick
AU  - McCabe NP
AD  - Department of Molecular Cardiology, NB50, The Cleveland Clinic Lerner Research 
      Institute, Cleveland, OH 44195, USA.
FAU - Madajka, Maria
AU  - Madajka M
FAU - Vasanji, Amit
AU  - Vasanji A
FAU - Byzova, Tatiana V
AU  - Byzova TV
LA  - eng
GR  - R01 DK060933/DK/NIDDK NIH HHS/United States
GR  - 5F32CA1172462/CA/NCI NIH HHS/United States
GR  - P30 AR050953/AR/NIAMS NIH HHS/United States
GR  - R01 CA126847/CA/NCI NIH HHS/United States
GR  - 1P30 AR-050953/AR/NIAMS NIH HHS/United States
GR  - DK060933/DK/NIDDK NIH HHS/United States
GR  - CA126847/CA/NCI NIH HHS/United States
GR  - R01 CA126847-07/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20080528
PL  - Netherlands
TA  - Clin Exp Metastasis
JT  - Clinical & experimental metastasis
JID - 8409970
SB  - IM
MH  - Animals
MH  - Bone Neoplasms/*secondary
MH  - Cell Line, Tumor
MH  - *Disease Models, Animal
MH  - Male
MH  - Mice
MH  - Mice, Transgenic
MH  - Neoplasm Transplantation/methods
MH  - Osteoblasts/metabolism/pathology
MH  - Osteoclasts/metabolism/pathology
MH  - Osteolysis/*pathology
MH  - Periosteum/metabolism/*pathology
MH  - Prostatic Neoplasms/*pathology
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Stem Cells/metabolism/pathology
PMC - PMC2864487
MID - NIHMS197330
EDAT- 2008/05/29 09:00
MHDA- 2008/09/17 09:00
PMCR- 2010/05/05
CRDT- 2008/05/29 09:00
PHST- 2007/08/15 00:00 [received]
PHST- 2008/04/26 00:00 [accepted]
PHST- 2008/05/29 09:00 [pubmed]
PHST- 2008/09/17 09:00 [medline]
PHST- 2008/05/29 09:00 [entrez]
PHST- 2010/05/05 00:00 [pmc-release]
AID - 10.1007/s10585-008-9175-1 [doi]
PST - ppublish
SO  - Clin Exp Metastasis. 2008;25(5):581-90. doi: 10.1007/s10585-008-9175-1. Epub 2008 
      May 28.